Neoleukin Therapeutics Investor Relations Material
Latest events
M&A Announcement
Neoleukin Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Neoleukin Therapeutics Inc
Access all reports
Neoleukin Therapeutics Inc. is a biopharmaceutical company focused on developing immunotherapies using its proprietary de novo protein design technology. The company’s approach involves creating novel proteins to target immune system pathways, with a particular focus on cancer and inflammatory diseases. Neoleukin’s therapies aim to harness and modulate the immune system to treat diseases more effectively. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
NLTX
Country
🇺🇸 United States